Cargando…

Serum high mobility group box-1 and osteoprotegerin levels are associated with peripheral arterial disease and critical limb ischemia in type 2 diabetic subjects

BACKGROUND: High mobility group box-1 (HMGB-1) is a nuclear protein also acting as inflammatory mediator, whilst osteoprotegerin (OPG), member of tumor necrosis factor receptor superfamily, is indicated as marker of vascular calcification. Peripheral artery disease (PAD) and type 2 diabetes (T2D) ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Giovannini, Silvia, Tinelli, Giovanni, Biscetti, Federico, Straface, Giuseppe, Angelini, Flavia, Pitocco, Dario, Mucci, Luciana, Landolfi, Raffaele, Flex, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549317/
https://www.ncbi.nlm.nih.gov/pubmed/28789654
http://dx.doi.org/10.1186/s12933-017-0581-z
_version_ 1783255952277897216
author Giovannini, Silvia
Tinelli, Giovanni
Biscetti, Federico
Straface, Giuseppe
Angelini, Flavia
Pitocco, Dario
Mucci, Luciana
Landolfi, Raffaele
Flex, Andrea
author_facet Giovannini, Silvia
Tinelli, Giovanni
Biscetti, Federico
Straface, Giuseppe
Angelini, Flavia
Pitocco, Dario
Mucci, Luciana
Landolfi, Raffaele
Flex, Andrea
author_sort Giovannini, Silvia
collection PubMed
description BACKGROUND: High mobility group box-1 (HMGB-1) is a nuclear protein also acting as inflammatory mediator, whilst osteoprotegerin (OPG), member of tumor necrosis factor receptor superfamily, is indicated as marker of vascular calcification. Peripheral artery disease (PAD) and type 2 diabetes (T2D) are clinical conditions characterized by elevated serum inflammatory markers and vascular calcification enhancement. The aim of this study was to investigate the potential role of HMGB-1, OPG and several inflammatory mediators such as C-reactive protein (HsCRP), tumor necrosis factor-alpha and interleukin-6 (IL-6) on the presence and severity of peripheral artery disease in patients with T2D. METHODS: In this retrospective observational study, we have analyzed HMGB-1, OPG and inflammatory cytokines serum levels in 1393 type 2 diabetic patients with PAD and without PAD (WPAD). RESULTS: HMGB-1 (7.89 ± 15.23 ng/mL), OPG (6.54 ± 7.76 pmol/L), HsCRP (15.6 ± 14.4 mg/L) and IL-6 (56.1 ± 28.6 pg/mL) serum levels were significantly higher in patients with PAD than in those WPAD (3.02 ± 8.12 ng/mL, P ˂ 0.001; 2.98 ± 2.01 pmol/L, P < 0.001; 7.05 ± 4.4 mg/L, P < 0.001; 37.5 ± 20.2 pg/mL, P < 0.001 respectively). Moreover HMGB-1 (P < 0.001), OPG (P < 0.001), HsCRP (P < 0.001) and IL-6 (P < 0.001) serum levels were positively correlated with clinical severity of PAD. HMGB-1 (adjusted OR 12.32; 95% CI 3.56–23.54, P = 0.023) and OPG (adjusted OR 3.53; 95% CI 1.54–6.15, P = 0.019) resulted independent determinants of PAD in patients with T2D after adjusting for the conventional cardiovascular risk factor and established inflammatory mediators. CONCLUSIONS: In T2D patients HMGB-1 and OPG serum levels are higher in patients affected by PAD and independently associated with its occurrence and clinical severity.
format Online
Article
Text
id pubmed-5549317
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-55493172017-08-11 Serum high mobility group box-1 and osteoprotegerin levels are associated with peripheral arterial disease and critical limb ischemia in type 2 diabetic subjects Giovannini, Silvia Tinelli, Giovanni Biscetti, Federico Straface, Giuseppe Angelini, Flavia Pitocco, Dario Mucci, Luciana Landolfi, Raffaele Flex, Andrea Cardiovasc Diabetol Original Investigation BACKGROUND: High mobility group box-1 (HMGB-1) is a nuclear protein also acting as inflammatory mediator, whilst osteoprotegerin (OPG), member of tumor necrosis factor receptor superfamily, is indicated as marker of vascular calcification. Peripheral artery disease (PAD) and type 2 diabetes (T2D) are clinical conditions characterized by elevated serum inflammatory markers and vascular calcification enhancement. The aim of this study was to investigate the potential role of HMGB-1, OPG and several inflammatory mediators such as C-reactive protein (HsCRP), tumor necrosis factor-alpha and interleukin-6 (IL-6) on the presence and severity of peripheral artery disease in patients with T2D. METHODS: In this retrospective observational study, we have analyzed HMGB-1, OPG and inflammatory cytokines serum levels in 1393 type 2 diabetic patients with PAD and without PAD (WPAD). RESULTS: HMGB-1 (7.89 ± 15.23 ng/mL), OPG (6.54 ± 7.76 pmol/L), HsCRP (15.6 ± 14.4 mg/L) and IL-6 (56.1 ± 28.6 pg/mL) serum levels were significantly higher in patients with PAD than in those WPAD (3.02 ± 8.12 ng/mL, P ˂ 0.001; 2.98 ± 2.01 pmol/L, P < 0.001; 7.05 ± 4.4 mg/L, P < 0.001; 37.5 ± 20.2 pg/mL, P < 0.001 respectively). Moreover HMGB-1 (P < 0.001), OPG (P < 0.001), HsCRP (P < 0.001) and IL-6 (P < 0.001) serum levels were positively correlated with clinical severity of PAD. HMGB-1 (adjusted OR 12.32; 95% CI 3.56–23.54, P = 0.023) and OPG (adjusted OR 3.53; 95% CI 1.54–6.15, P = 0.019) resulted independent determinants of PAD in patients with T2D after adjusting for the conventional cardiovascular risk factor and established inflammatory mediators. CONCLUSIONS: In T2D patients HMGB-1 and OPG serum levels are higher in patients affected by PAD and independently associated with its occurrence and clinical severity. BioMed Central 2017-08-08 /pmc/articles/PMC5549317/ /pubmed/28789654 http://dx.doi.org/10.1186/s12933-017-0581-z Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Original Investigation
Giovannini, Silvia
Tinelli, Giovanni
Biscetti, Federico
Straface, Giuseppe
Angelini, Flavia
Pitocco, Dario
Mucci, Luciana
Landolfi, Raffaele
Flex, Andrea
Serum high mobility group box-1 and osteoprotegerin levels are associated with peripheral arterial disease and critical limb ischemia in type 2 diabetic subjects
title Serum high mobility group box-1 and osteoprotegerin levels are associated with peripheral arterial disease and critical limb ischemia in type 2 diabetic subjects
title_full Serum high mobility group box-1 and osteoprotegerin levels are associated with peripheral arterial disease and critical limb ischemia in type 2 diabetic subjects
title_fullStr Serum high mobility group box-1 and osteoprotegerin levels are associated with peripheral arterial disease and critical limb ischemia in type 2 diabetic subjects
title_full_unstemmed Serum high mobility group box-1 and osteoprotegerin levels are associated with peripheral arterial disease and critical limb ischemia in type 2 diabetic subjects
title_short Serum high mobility group box-1 and osteoprotegerin levels are associated with peripheral arterial disease and critical limb ischemia in type 2 diabetic subjects
title_sort serum high mobility group box-1 and osteoprotegerin levels are associated with peripheral arterial disease and critical limb ischemia in type 2 diabetic subjects
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549317/
https://www.ncbi.nlm.nih.gov/pubmed/28789654
http://dx.doi.org/10.1186/s12933-017-0581-z
work_keys_str_mv AT giovanninisilvia serumhighmobilitygroupbox1andosteoprotegerinlevelsareassociatedwithperipheralarterialdiseaseandcriticallimbischemiaintype2diabeticsubjects
AT tinelligiovanni serumhighmobilitygroupbox1andosteoprotegerinlevelsareassociatedwithperipheralarterialdiseaseandcriticallimbischemiaintype2diabeticsubjects
AT biscettifederico serumhighmobilitygroupbox1andosteoprotegerinlevelsareassociatedwithperipheralarterialdiseaseandcriticallimbischemiaintype2diabeticsubjects
AT strafacegiuseppe serumhighmobilitygroupbox1andosteoprotegerinlevelsareassociatedwithperipheralarterialdiseaseandcriticallimbischemiaintype2diabeticsubjects
AT angeliniflavia serumhighmobilitygroupbox1andosteoprotegerinlevelsareassociatedwithperipheralarterialdiseaseandcriticallimbischemiaintype2diabeticsubjects
AT pitoccodario serumhighmobilitygroupbox1andosteoprotegerinlevelsareassociatedwithperipheralarterialdiseaseandcriticallimbischemiaintype2diabeticsubjects
AT mucciluciana serumhighmobilitygroupbox1andosteoprotegerinlevelsareassociatedwithperipheralarterialdiseaseandcriticallimbischemiaintype2diabeticsubjects
AT landolfiraffaele serumhighmobilitygroupbox1andosteoprotegerinlevelsareassociatedwithperipheralarterialdiseaseandcriticallimbischemiaintype2diabeticsubjects
AT flexandrea serumhighmobilitygroupbox1andosteoprotegerinlevelsareassociatedwithperipheralarterialdiseaseandcriticallimbischemiaintype2diabeticsubjects